Back

Prognostic impact of mitral valve geometry in patients with secondary mitral regurgitation: a secondary analysis of the MITRA-FR trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Imaging in mitral regurgitation: what tools do we need? Mitral Valve Regurgitation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Paul Ng

University Hospital of Nantes, Nantes (France)

8 More presentations in this session

Presentation thumbnail
Prognostic impact of left ventricular myocardial work in patients undergoing surgery for primary mitral regurgitation
Doctor T. Nabeta (Sagamihara, JP)
Abstract Slides
Presentation thumbnail
Prevalence, characteristics, and long-term outcomes of patients with mitral annular disjunction undergoing surgery for degenerative mitral regurgitation
Doctor K. Lodin (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Cardiac chamber three-dimensional volumes and deformation predict clinical outcomes in chronic mitral regurgitation
Associate Professor D. Cramariuc (Bergen, NO)
Abstract Slides
Presentation thumbnail
Prognostic value of exercise right ventricular-pulmonary arterial coupling in primary mitral regurgitation
Doctor S. Moura Ferreira (Hasselt, BE)
Abstract Slides
Presentation thumbnail
Atrial functional and ventricular functional mitral regurgitation: definitions, epidemiology, and prognostic implications
Doctor S. Koschatko (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Imaging in mitral regurgitation: what tools do we need?

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Post-procedural mitral regurgitation as an independent predictor of morbidity and mortality outcomes
thumbnail
Congress Presentation
Prognostic impact of normalizing 3D mitral RegVol to LAVmax in HFrEF patients with ventricular secondary MR
thumbnail
Congress Presentation
Mitral valve repair in heart failure: a comparative analysis to MITRA-FR and COAPT trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources